Structure Therapeutics (NASDAQ:GPCR) Given New $110.00 Price Target at Citizens Jmp

Structure Therapeutics (NASDAQ:GPCR) had its price target decreased by analysts at Citizens Jmp from $113.00 to $110.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price target would suggest a potential upside of 111.80% from the stock’s previous close.

A number of other research analysts have also issued reports on GPCR. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research note on Friday. Wall Street Zen raised Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. HC Wainwright lowered their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $111.18.

Structure Therapeutics Stock Down 1.3%

Shares of GPCR traded down $0.68 during midday trading on Friday, reaching $51.94. 100,729 shares of the stock were exchanged, compared to its average volume of 892,462. The stock’s 50 day simple moving average is $47.36 and its 200 day simple moving average is $54.20. The company has a market cap of $3.69 billion, a P/E ratio of -59.95 and a beta of -1.43. Structure Therapeutics has a twelve month low of $15.86 and a twelve month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, analysts predict that Structure Therapeutics will post -1.64 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Structure Therapeutics by 18.5% during the second quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock worth $1,124,000 after purchasing an additional 8,444 shares during the last quarter. Invesco Ltd. increased its stake in shares of Structure Therapeutics by 7.6% in the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock valued at $8,805,000 after purchasing an additional 30,162 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Structure Therapeutics by 474.9% in the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after purchasing an additional 145,434 shares during the last quarter. Jump Financial LLC raised its holdings in shares of Structure Therapeutics by 105.9% during the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock worth $1,311,000 after buying an additional 32,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Structure Therapeutics during the 2nd quarter worth $3,480,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.